Showing results (201-210 of 335) with videos related to
Sort By:
Pageof 34
Oncology|March 5, 2009
Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancerJoanna M Brell, Khalid Matin, Terry Evans, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinomaMace L Rothenberg, Bonnie LaFleur, Donna E Levy, et al.Cancer Chemotherapy and Pharmacology|March 11, 2014
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumorsKelly K Curtis, John Sarantopoulos, Donald W Northfelt, et al.Oncology|April 15, 2010
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomasShelly S Lo, Alok A Khorana, Milind Javle, et al.Investigational New Drugs|August 25, 2011
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapyRamesh K Ramanathan, Joe J Stephenson, Glen J Weiss, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2005
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancerH Oettle, D Richards, R K Ramanathan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2009
Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignanciesWilliam C Zamboni, Suresh Ramalingam, David M Friedland, et al.ESMO Open|August 30, 2017
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohortHoward A Burris, Suzanne Bakewell, Johanna C Bendell, et al.Annals of Surgical Oncology|November 25, 2010
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancerPhilip Q Bao, Ramesh K Ramanathan, Alyssa Krasinkas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2015
Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)Gregory N Dietsch, Tressa D Randall, Raphael Gottardo, et al.Pageof 34